EGFR and neoplasm: In contrast to single-pathway inducers, SH003 may amplify via multi-node interference, sensitizing ferroptosis-resistant tumor types such as triple-negative breast cancer (TNBC) and epidermal growth factor receptor (EGFR)-mutant NSCLC [36,37,38].